Predictors of infliximab efficacy in patients with severe attack of ulcerative colitis
Aim of investigation. Biological therapy by monoclonal antibodies against tumor necrosis factor (infliximab) allows to avoid colectomy at steroid-resistant severe attack of ulcerative colitis. High cost of such treatment and risk of adverse events related to it requires definition of strict indicati...
Saved in:
| Main Authors: | A. O. Golovenko, I. L. Khalif, O. V. Golovenko, V. V. Veselov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Gastro LLC
2013-10-01
|
| Series: | Российский журнал гастроэнтерологии, гепатологии, колопроктологии |
| Subjects: | |
| Online Access: | https://www.gastro-j.ru/jour/article/view/1233 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Results of non-medical switching from original infliximab to its Russian biosimilar in patients with ulcerative colitis
by: Maria I. Timanovskaia, et al.
Published: (2025-01-01) -
How We Can Personalize the Infliximab Use in Ulcerative Patients
by: Mohammed Hussien Ahmed, et al.
Published: (2025-06-01) -
Efficacy and Safety of Vedolizumab with Glucocorticoids vs Infliximabin Severe Ulcerative Colitis: A Retrospective Study
by: Zhang C, et al.
Published: (2025-06-01) -
Case Report: Hemolytic anemia secondary to infliximab treatment in a patient with ulcerative colitis
by: Gerolamo Bevivino, et al.
Published: (2025-03-01) -
Infliximab for patients with moderate to severely active ulcerative colitis: an updated meta-analysis of randomized controlled trials
by: Min Zhang, et al.
Published: (2025-07-01)